redirectt-1 study: dual targeting of bcma and gprc5d in rrmm pts with teclistamab and talquetamab
Published 1 year ago • 449 plays • Length 9:41
Download video MP4
Download video MP3
Similar videos
-
5:20
teclistamab talquetamab targeting bcma and gprc5d shows promising efficacy in patients with rrmm
-
8:43
results from monumental-1: first-in-human study of talquetamab in pts with rr multiple myeloma
-
9:57
teclistamab, a bcma × cd3 bispecific antibody, in pts with rrmm: updated phase 1 results
-
7:24
updated study results of bcma/cd19 dual-targeting car-t gc012f for rrmm patients
-
5:54
redirectt-1 results: teclistamab talquetamab in r/r multiple myeloma
-
7:25
updated phase 1 results of teclistamab, a bcma × cd3 bispecific antibody, in rrmm
-
6:58
gprc5d-targeted car t-cell therapy for rrmm: phase 1 study outcomes of bms-986393 (cc-95266)
-
6:18
talquetamab and teclistamab in rrmm: updated results from redirectt-1 | yael cohen, md | ims 2024
-
6:36
updated results of a phase 1, first-in-human study of talquetamab in relapsed refractory mm
-
7:02
talquetamab in pts with relapsed/refractory multiple myeloma: phase 1/2 results from monumental-1
-
6:58
phase 1 study of the gprc5dxcd3 bispecific talquetamab in patients with rr multiple myeloma
-
5:53
evaluation of teclistamab in rrmm patients following exposure to other bcma-targeted agents
-
0:36
promise of gprc5d-targeted car-t therapies in multiple myeloma
-
8:06
clinical activity of bms-986393, a car t cell therapy directed at gprc5d, in pts with rrmm
-
8:12
evaluating teclistamab in relapsed and/or refractory multiple myeloma
-
7:44
ash23: abbv-383 bcma x cd3 bispecific antibody for relapsed/refractory myeloma | ravi vij, md, mba
-
1:38
using bcma-targeting agents in earlier lines of treatment for multiple myeloma
-
2:33
teclistamab approval for multiple myeloma treatment | ross firestone, md, phd | asco 2023
-
4:46
which bispecific antibody should be used first in patients with myeloma?
Clip.africa.com - Privacy-policy